Gjettum

Researchers are evaluating the safety and effectiveness of stopping antibiotic treatment early in adults hospitalized with respiratory viral infections. This study focuses on patients with moderately severe disease who test positive for respiratory viruses such as influenza, respiratory syncytial virus, parainfluenza virus, or human metapneumovirus. The goal is to determine if early discontinuation of antibiotics leads to similar clinical outcomes compared to continuing antibiotic therapy, aiming to reduce unnecessary antibiotic use and combat antimicrobial resistance. Participants are randomly assigned to either stop antibiotic therapy as started by their admitting physician or to continue antibiotic therapy without changes. The study monitors early clinical response at 120 hours after randomization, defined by survival with symptom improvement and no need for rescue antibiotics. Secondary assessments include mortality rates, hospital stay duration, antibiotic use, and readmission rates, all measured during hospital admission and up to 30 days after discharge. During the trial, participants undergo nasopharyngeal swab testing to confirm viral infection and are monitored closely for symptoms, survival, and antibiotic use. Researchers evaluate clinical response at 120 hours and track outcomes such as mortality, hospital stay length, and antibiotic doses until discharge and 30 days later. The study aims to gather detailed safety and efficacy data over the hospital stay and follow-up period, supporting more targeted antibiotic use in viral respiratory infections.

Researchers are investigating atrial fibrillation AF, a common heart rhythm problem linked to 20-30% of all strokes. Detecting AF early after a stroke is important because AF-related strokes tend to be more severe, but the best timing and devices for screening are not yet well defined. This study aims to find out if screening for AF right after stroke symptoms begin detects more cases than screening after hospital discharge and whether a 3-lead ECG device improves detection compared to a 1-lead patch recorder. The study involves patients admitted with acute stroke who do not have AF at admission or have paroxysmal AF but show normal heart rhythm when admitted. Participants will receive 48 hours of continuous heart monitoring in the hospital, followed by another 48 hours after discharge. A subgroup will also perform intermittent handheld ECG recordings three times daily for 30 seconds over three days during their hospital stay. The study compares continuous versus intermittent monitoring and different device types to see which detects AF more effectively. During their participation, patients will undergo heart rhythm monitoring with ECG devices and complete handheld ECG tests if selected. Researchers will track AF detection rates during 48 to 96 hours post-stroke, comparing results based on timing and device type. The study evaluates outcomes like the rate of AF detection with different monitoring strategies, aiming to improve early diagnosis to help prevent recurrent strokes. Participation includes monitoring during hospital stay and after discharge, with follow-up lasting up to about four days of recording.

Researchers are conducting a randomized trial comparing two treatments for patients who have undergone incomplete endoscopic removal of early colon cancer. The study aims to evaluate the benefits, potential harms, burdens, environmental impact, and cost-effectiveness of endoscopic full thickness resection eFTR, a minimally invasive procedure using a colonoscope, compared to standard surgery. The main goals are to assess serious adverse events within 30 days and colon cancer recurrence or spread to lymph nodes or distant sites at 3 years after treatment. Participants are randomly assigned to one of two groups. One group receives surgery following current guidelines, which may include open, laparoscopic, or robotic segmental bowel resection targeting the lymphatic drainage area of the cancer. The other group undergoes eFTR using approved devices, where the scar from the previous removal is identified, documented, and then removed en bloc with the eFTR device mounted on the colonoscope. This design allows a direct comparison of these two approaches. During the study, participants will be closely monitored for safety, cancer recurrence, and other outcomes. Assessments include tracking severe adverse events within 30 days, cancer status at 1, 3, and 5 years, quality of life and functional outcomes, length of hospital stay, readmission rates, and environmental footprint of the procedures. The study also measures technical success and procedure duration. Overall, the trial lasts several years to fully evaluate long-term cancer control and safety.

Researchers are conducting an observational study to understand how new immunotherapies are used in treating multiple myeloma and related conditions in Norway. The study aims to fill knowledge gaps, provide evidence for future trials, and help develop guidelines for monitoring and managing side effects to improve patient survival and quality of life. This research focuses on patients with multiple myeloma, primary plasma cell leukemia, and AL amyloidosis. Participants are observed while receiving immunotherapies including Teclistamab, Elranatamab, Talquetamab, Idecabtagene vicleucel, and Ciltacabtagene Autoleucel as part of their routine care outside of clinical trials. The study monitors how these treatments are used in real-world settings, including dosing and administration. There is no assigned treatment group or placebo instead, the study collects data on treatments given during regular healthcare. Throughout the study, participants response to treatment, progression-free survival, time to next treatment, overall survival, and adverse events are tracked for up to ten years. Researchers collect data on infections, antibiotic resistance, airway viruses, and use of antimicrobial prophylaxis during therapy. This long-term monitoring aims to provide comprehensive safety and effectiveness information to guide future care and research.

Researchers are evaluating whether stroke patients who have recently taken Factor Xa FXa inhibitors, a type of blood thinner, can safely receive intravenous thrombolysis IVT, a clot-busting emergency treatment. Current guidelines advise against IVT within 48 hours of FXa inhibitor use due to bleeding risks, but new studies suggest IVT might be safe for these patients. This phase III multicenter trial aims to provide solid evidence on the safety and effectiveness of IVT in this group, potentially changing stroke treatment guidelines to help more patients. Participants are randomly assigned to one of two groups one receiving IVT with either alteplase or tenecteplase according to hospital procedures, and the other receiving standard care with aspirin but no IVT. The IVT group gets specific doses of the drugs either as an infusion or a single bolus. The study compares early neurological improvement and safety outcomes between these groups. The trial runs from 2025 to 2029, with patient follow-up lasting 90 days. During the study, researchers monitor neurological function using standardized scales such as the NIH Stroke Scale and brain imaging to measure infarct size and bleeding events. They also assess functional outcomes and mortality up to 90 days after treatment. Safety monitoring includes checking for symptomatic brain bleeding within 36 hours. The trial uses a randomized, open-label design with blinded outcome assessment, aiming to enroll 300 patients across multiple centers.